Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
NCT00666081
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Study Cancelled before enrollment
Conditions
Cancer
Interventions
DRUG:
GSK690693
Sponsor
GlaxoSmithKline